MODEM Dementia Evidence Database

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer’s disease

Herrmann, Nathan, Gauthier, Serge, Boneva, Neli, Lemming, Ole Michael

Background: Agitation and aggression in Alzheimer’s disease (AD) are amongst the most serious of neuropsychiatric symptoms, and contribute to poor outcomes and worse quality of life. Previous studies have suggested a benefit for memantine on agitation and aggression, but none have examined its efficacy in community-dwelling patients with significant agitation and aggression at baseline, utilizing […]

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors

Grossberg, George T., Manes, Facundo, Allegri, Ricardo F., Gutiérrez-Robledo, Luis Miguel, Gloger, Sergio, Xie, Lei, Jia, X. Daniel, Pejović, Vojislav, Miller, Michael L., Perhach, James L., Graham, Stephen M.

Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease

Grossberg, G., Cummings, J., Frolich, L., Bellelli, G., Molinuevo, J. L., Krahnke, T., Strohmaier, C.

Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]

A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Grimaldi, Luigi Maria, Zappalà, Giuseppe, Iemolo, Francesco, Castellano, Anna, Ruggieri, Stefano, Bruno, Giuseppe, Paolillo, Andrea

Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in AD. We evaluated the safety and efficacy of IFNβ1a in subjects affected by mild-to-moderate AD in […]

The memory support system for mild cognitive impairment: randomized trial of a cognitive rehabilitation intervention

Greenaway, M. C., Duncan, N. L., Smith, G. E.

Objective: Individuals with amnestic mild cognitive impairment (MCI) have few empirically based treatment options for combating their memory loss. This study sought to examine the efficacy of a calendar/notebook rehabilitation intervention, the memory support system (MSS), for individuals with amnestic MCI.; Methods: Forty individuals with single domain amnestic MCI and their program partners were randomized […]

Robot services for elderly with cognitive impairment: testing usability of graphical user interfaces

Granata, C., Pino, M., Legouverneur, G., Vidal, J. S., Bidaud, P., Rigaud, A. S.

Background: Socially assistive robotics for elderly care is a growing field. However, although robotics has the potential to support elderly in daily tasks by offering specific services, the development of usable interfaces is still a challenge. Since several factors such as age or disease-related changes in perceptual or cognitive abilities and familiarity with computer technologies […]

A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial

Gitlin, Laura N, Winter, Laraine, Dennis, Marie P., Hodgson, Nancy, Hauck, Walter W.

Context: Optimal treatment to postpone functional decline in patients with dementia is not established.; Objective: To test a nonpharmacologic intervention realigning environmental demands with patient capabilities.; Design, Setting, and Participants: Prospective 2-group randomized trial (Care of Persons with Dementia in their Environments [COPE]) involving patients with dementia and family caregivers (community-living dyads) recruited from March […]

A non-pharmacologic approach to address challenging behaviors of Veterans with dementia: description of the tailored activity program-VA randomized trial

Gitlin, Laura N, Mann, William C, Vogel, W, Arthur, Paul B

Background: Behavioral symptoms accompanying dementia are associated with increased health care costs, reduced quality of life and daily functioning, heightened family caregiver burden, and nursing home placement. Standard care typically involves pharmacologic agents, but these are, at best, modestly effective, carry serious risks, including mortality, and do not address behavioral symptoms families consider most distressful […]

Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease

Geschwind, M. D., Kuo, A. L., Wong, K. S., Haman, A., Devereux, G., Raudabaugh, B. J., Johnson, D. Y., Torres-Chae, C. C., Finley, R., Garcia, P., Thai, J. N., Cheng, H. Q., Neuhaus, J. M., Forner, S. A., Duncan, J. L., Possin, K. L., DeArmond, S. J., Prusiner, S. B., Miller, B. L.

Objective: To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD).; Methods: This NIH/National Institute on Aging-funded, double-blinded, placebo-controlled, stratified randomization treatment trial was conducted at the University of California, San Francisco from February 2005 through May 2009 (ClinicalTrials.gov, NCT00183092). Subjects were randomized (50:50) to quinacrine (300 mg daily) or placebo with inpatient […]

Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study

Gareri, Pietro, Putignano, Daria, Castagna, Alberto, Cotroneo, Antonino Maria, De Palo, Grazia, Fabbo, Andrea, Forgione, Luigi, Giacummo, Attilio, Lacava, Roberto, Marino, Saverio, Simone, Maurizio, Zurlo, Amedeo, Putignano, Salvatore

Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]

This database contains 231 abstracts archived under the term: "ADLs/IADLs"

This database contains 231 studies, archived under the term: "ADLs/IADLs"